Dataset Information

PU1 interactome in human monocyte derived dendritic cells

ABSTRACT: Human monocyte-derived DC were cultured at a density of 0.5x10E6 cells/ml in RPMI-1640 supplemented with 10% FCS, 1% Pen/Strep, 10 ng/ml GM-CSF and 10 ng/ml IL4. At day 7, they were stimulated or not with 500 ng/ml LPS. Cells were collected at day 10. Whole cell lystaes from 2x10E8 cells were used for immunoprecipiation with PU.1 (T-21 SantaCruz) antibody. IgG was used as control.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens

SUBMITTER: Laura Gutierrez

PROVIDER: MSV000083175 | MassIVE | Fri Nov 30 05:12:00 GMT 2018

SECONDARY ACCESSION(S): PXD011903

REPOSITORIES: MassIVE

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

Comparison of the PU.1 transcriptional regulome and interactome in human and mouse inflammatory dendritic cells.

Scheenstra Maaike R MR Martínez-Botía Patricia P Acebes-Huerta Andrea A Brouwer Rutger W W RWW Caballero-Sánchez Noemí N Gillemans Nynke N De Bleser Pieter P Nota Benjamin B De Cuyper Iris M IM Salunkhe Vishal V Woltman Andrea M AM van de Laar Lianne L Rijkers Erikjan E Demmers Jeroen A A JAA van IJcken Wilfred F J WFJ Philipsen Sjaak S van den Berg Timo K TK Kuijpers Taco W TW Gutiérrez Laura L

Journal of leukocyte biology 20201202

Dendritic cells (DCs) are key immune modulators and are able to mount immune responses or tolerance. DC differentiation and activation imply a plethora of molecular and cellular responses, including transcriptional changes. PU.1 is a highly expressed transcription factor in DCs and coordinates relevant aspects of DC biology. Due to their role as immune regulators, DCs pose as a promising immunotherapy tool. However, some of their functional features, such as survival, activation, or migration, a ...[more]

PMID: 33289106

Similar Datasets

Project description:miRNA profiling of CD34+ derived, in vitro-generated Langerhans cells (LCs) and interstitial-type dendritic cells (intDCs). Epidermal Langerhans cells (LCs) form a network of dendritic cells (DCs) in basal/suprabasal layers of the skin and are characterized by a unique phenotype (CD207+ CD1abright CD324+ CD11b-). Due to their specific location at body surfaces, LCs are constantly exposed to environmental stimuli. Conversely, interstitial-type DCs (intDCs) are located in adjacent tissues and can be discriminated from LCs phenotypically (CD207- CD1adim CD324- CD11b+). These DCs constitute a second line of defense against pathogens that have crossed the epithelial barrier. During development both DC subsets originally arise from myeloid progenitor cells via monocyte-committed intermediates in response to specific microenvironmental signals. Additionally certain pools of DCs can be replenished by tissue resident cells or monocytes in response to specific microenvironmental signals (2, 4, 5). In vitro generated GM-CSF/IL-4-dependent DCs derived either from CD14+ monocytes or via CD14+CD11b+ monocyte intermediates from CD34+ progenitor cells share many characteristics with intDCs in vivo. On the other hand, LCs generated from CD34+ cells under serum-free TGF-beta1-dependent conditions phenotypically resemble epidermal-resident LCs. Since these two DC subsets are of considerable interest for clinical cell therapy studies, an improved understanding of their development and function is of substantial relevance. To identify differentially expressed miRNAs in DC subsets, we performed a miRNA screen. Therefore, we generated LCs or intDCs from human CD34+ cord blood haematopoietic progenitor cells as described. For intDCs, CD34+ cells (1 x 104 to 2 x 104/ml per well) were cultured in 24-well tissue culture plates in serum free CellGro® DC medium (CellGenix, Freiburg, Germany) supplemented with GM-CSF (100 ng/ml), SCF (20 ng/ml), FL (50 ng/ml) and TNFalpha (2.5 ng/ml) for 3-5 days and subsequently with GM-CSF (100 ng/ml) and IL-4 (2.5 ng/ml) for 4-5 days. For LCs, CD34+ cells (1 x 104 to 2 x 104/ml per well) were cultured in 24-well tissue culture plates in serum free CellGro® DC medium (CellGenix, Freiburg, Germany) supplemented with GM-CSF (100 ng/ml), SCF (20 ng/ml), FL (50 ng/ml), TNFalpha (2.5 ng/ml) and TGF-beta1 (0.5 ng/ml). The well-established immunophenotype of LCs (CD1ahi CD11b- CD207+ CD324+) and intDCs (CD1a+ CD11b+ CD207- CD324-) was confirmed by FACS. These two DC subsets were purified and submitted to differential miRNA profiling.